Patients with immune-mediated inflammatory diseases (IMIDs) undergoing immunosuppressive therapy are at increased risk of herpes zoster (HZ).1 In line with international guidelines, the French national health authority updated the vaccination strategy against varicella zoster virus (VZV) in March 2024 and now recommends that immunocompromised persons aged ≥ 18 years be vaccinated with the recombinant VZV vaccine.2-4
